1. Home
  2. ORIQ vs WHWK Comparison

ORIQ vs WHWK Comparison

Compare ORIQ & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORIQ
  • WHWK
  • Stock Information
  • Founded
  • ORIQ 2024
  • WHWK 2007
  • Country
  • ORIQ Singapore
  • WHWK United States
  • Employees
  • ORIQ N/A
  • WHWK N/A
  • Industry
  • ORIQ
  • WHWK Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORIQ
  • WHWK Health Care
  • Exchange
  • ORIQ Nasdaq
  • WHWK Nasdaq
  • Market Cap
  • ORIQ 87.6M
  • WHWK 95.2M
  • IPO Year
  • ORIQ 2025
  • WHWK N/A
  • Fundamental
  • Price
  • ORIQ $10.18
  • WHWK $2.09
  • Analyst Decision
  • ORIQ
  • WHWK
  • Analyst Count
  • ORIQ 0
  • WHWK 0
  • Target Price
  • ORIQ N/A
  • WHWK N/A
  • AVG Volume (30 Days)
  • ORIQ 8.0K
  • WHWK 305.6K
  • Earning Date
  • ORIQ 01-01-0001
  • WHWK 11-06-2025
  • Dividend Yield
  • ORIQ N/A
  • WHWK N/A
  • EPS Growth
  • ORIQ N/A
  • WHWK N/A
  • EPS
  • ORIQ N/A
  • WHWK N/A
  • Revenue
  • ORIQ N/A
  • WHWK $14,384,000.00
  • Revenue This Year
  • ORIQ N/A
  • WHWK N/A
  • Revenue Next Year
  • ORIQ N/A
  • WHWK N/A
  • P/E Ratio
  • ORIQ N/A
  • WHWK N/A
  • Revenue Growth
  • ORIQ N/A
  • WHWK N/A
  • 52 Week Low
  • ORIQ $9.98
  • WHWK $1.39
  • 52 Week High
  • ORIQ $10.20
  • WHWK $3.81
  • Technical
  • Relative Strength Index (RSI)
  • ORIQ N/A
  • WHWK 46.93
  • Support Level
  • ORIQ N/A
  • WHWK $2.01
  • Resistance Level
  • ORIQ N/A
  • WHWK $2.27
  • Average True Range (ATR)
  • ORIQ 0.00
  • WHWK 0.16
  • MACD
  • ORIQ 0.00
  • WHWK -0.03
  • Stochastic Oscillator
  • ORIQ 0.00
  • WHWK 22.92

About ORIQ Origin Investment Corp I Ordinary Shares

Origin Investment Corp I is a blank check company.

About WHWK Whitehawk Therapeutics Inc. Common Stock

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Share on Social Networks: